The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Pfizer Inc. (NYSE:PFE) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the ...

The global Biosimilar Pipeline Analysis market is expected to grow at 17.8% CAGR from 2025 to 2032. Latest Research Report on the Biosimilar Pipeline Analysis Market Size, Status, and Forecast for ...

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Today, companies like Nestle India, Punjab National Bank, Marico, Vedanta, Pfizer, Oil and Natural Gas Corporation, and ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...